Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SUV39H2 | Q9H5I1 | 10/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691516 | 0.88 | RAB9A (0.60) | LMNASUV39H2RAB9ANPC1KDM4E | |
| SCHEMBL1691402 | 0.84 | RAB9A (0.63) | LMNARAB9ANPC1KDM4EMAPT | |
| SCHEMBL1691364 | 0.82 | RAB9A (0.60) | LMNARAB9ANPC1KDM4EMAPT | |
| SCHEMBL1691462 | 0.80 | RAB9A (0.66) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL1691855 | 0.79 | FFAR1 (0.42) | SUV39H2RAB9ANPC1KDM4EMAPT | |
| SCHEMBL1691504 | 0.78 | RAB9A (0.53) | LMNARAB9ANPC1KDM4EMAPT | |
| SCHEMBL28889673 | 0.77 | RAB9A (0.45) | LMNASUV39H2RAB9ANPC1KDM4E | |
| SCHEMBL1691574 | 0.77 | RAB9A (0.58) | LMNARAB9ANPC1KDM4EMAPT | |
| SCHEMBL28401383 | 0.77 | RAB9A (0.45) | SUV39H2RAB9ANPC1KDM4EMAPT | |
| SCHEMBL28889668 | 0.76 | RAB9A (0.44) | SUV39H2RAB9ANPC1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | disclosed |
| US-20140206662-A1 | Imidazopyridine Compounds | PROXIMAGEN LTD. (GB) | 2014-07-24 | — | — | US | disclosed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| EP-2376490-A1 | IMIDAZOPYRIDINE COMPOUNDS | Proximagen Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010188-A1 | Imidazopyridine Compounds | SSB, MIF, IDO1 | LMNA 2516/4885SUV39H2 3930/4885RAB9A 3798/4885 |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | SSB, MIF, IDO1 | LMNA 2516/4885SUV39H2 3930/4885RAB9A 3798/4885 |
| US-20140206662-A1 | Imidazopyridine Compounds | SSB, NFKBIA, TPMT | LMNA 3526/4885SUV39H2 3286/4885RAB9A 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.